Search Drug Information, Interactions, Images, Dosage & Side Effects

BICSTaR suggests efficacy of start/switch to bictegravir/emtricitabine/TAF in PLHIV 25 Nov 2020

Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.

Proton beam therapy combined with intravitreal anti-VEGF safe, effective for eAMD

25 Nov 2020

NALA: Neratinib–capecitabine role in HER2-positive MBC confirmed in Asians

25 Nov 2020

Healthy body composition at midlife tied to successful ageing in men

25 Nov 2020

Rosacea linked to hypertension, dyslipidaemia

25 Nov 2020

AF patients not on anticoagulation therapy at higher risk of death after TAVR

25 Nov 2020

Durable treatment response seen with dapagliflozin-saxagliptin add-on in T2D patients on metformin

25 Nov 2020

Singapore’s vaccination programme successful; kids, teens safe from measles, rubella

25 Nov 2020

Oral prednisolone strikes out in children with acute wheeze

25 Nov 2020

Vitamin D deficient COVID-19 patients at risk of morbidity, mortality

25 Nov 2020

Risk factor modification for AMI needed in pregnant women

25 Nov 2020

Putting patients at the heart of care: Sacubitril/valsartan improves physical and social activity impairment in HFrEF 23 Nov 2020;
Heart failure (HF) is a global public health concern, affecting about 38 million individuals globally.1 Despite significant medical advances, HF remains a chronic and progressive condition that can negatively affect patients’ quality of life (QoL).2,3 In this case study, Dr Abdul Muizz shares his clinical experience in managing a patient with HF and reduced ejection fraction (HFrEF), following the percutaneous coronary intervention, showing how the initiation of sacubitril/valsartan therapy (an angiotensin receptor/neprilysin inhibitor [ARNI]) changed the clinical outcome of this patient.

From clinical trials to real-world evidence: Tofacitinib in the treatment of rheumatoid arthritis

20 Nov 2020

Echinocandins boost the antifungal armamentarium

17 Nov 2020

Empagliflozin not just another SGLT2i: Cardio-renal benefits extend to HF with or without diabetes

Roshini Claire Anthony, 13 Nov 2020

Ozempic

Contents : Semaglutide

Indications/Uses : Adjunct to diet & exercise in adults w/ insufficiently controlled type 2 DM as monotherapy when metformin is inappropriate due to intolerance or CIs; in addition to other medicinal products.

Erleada

Contents : Apalutamide

Indications/Uses : Non-metastatic castration-resistant prostate cancer in adult men who are at high risk of developing metastatic disease.

Galvus Met

Contents : Per 50 mg/500 mg FC tab Vildagliptin 50 mg, metformin HCl 500 mg. Per 50 mg/850 mg FC tab Vildagliptin 50 mg, metformin HCl 850 mg. Per 50 mg/1,000 mg FC tab Vildagliptin 50 mg, metformin HCl 1,000 mg

Indications/Uses : Type 2 DM inadequately controlled on metformin alone or who are already treated w/ combination of vildagliptin & metformin as separate tab. In triple combination therapy w/ sulphonylurea as an adjunct to diet & exercise in patients inadequately controlled w/ metformin & sulphonylurea. In triple combination therapy w/ insulin as an adjunct to diet & exercise to improve glycaemic control in adult patients when stable dose of insulin & metformin alone do not provide adequate glycaemic control. Initial therapy in patients w/ type 2 DM whose diabetes is inadequately controlled by diet & exercise alone.

Xofluza

Contents : Baloxavir marboxil

Indications/Uses : Acute uncomplicated influenza in patients ≥12 yr who have been symptomatic for no >48 hr.

Forxiga

Contents : Dapagliflozin

Indications/Uses : Adjunct to diet & exercise to improve glycaemic control in adults ≥18 yr w/ type 2 DM as monotherapy; add-on combination w/ glucose-lowering medicinal product eg, insulin; as initial combination therapy w/ metformin (includes poor prospects for response to metformin monotherapy). Reduce risk of hospitalization for heart failure in adults w/ type 2 DM & established CV disease or multiple CV risk factors.

Crestor

Contents : Rosuvastatin Ca

Indications/Uses : Reduction of elevated total cholesterol (total-C), LDL-C, apolipoprotein B (ApoB), total-C: HDL-C ratio triglycerides & increasing HDL-C in hyperlipidemic & dyslipidemic conditions. Reduction of total mortality & risk of major CV events in adults w/ increased risk of atherosclerotic CV disease based on presence of CV disease risk markers. Primary dysbetalipoproteinemia (type III hyperlipoproteinemia); primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia & severe non-familial hypercholesterolaemia); combined (mixed) dyslipidaemia (type IIb); homozygous familial hypercholesterolaemia. Adjunctive therapy to diet to slow progression of atherosclerosis in adults as part of treatment strategy to lower total-C & LDL-C to target levels. Adjunct to diet to reduce total-C, LDL-C & ApoB levels in adolescents at least 1 yr post-menarche, 10-17 yr w/ heterozygous familial hypercholesterolaemia.

Cosyrel

Contents : Per 5 mg/5 mg FC tab Bisoprolol fumarate 5 mg, perindopril arginine 5 mg. Per 5 mg/10 mg FC tab Bisoprolol fumarate 5 mg, perindopril arginine 10 mg. Per 10 mg/10 mg FC tab Bisoprolol fumarate 10 mg, perindopril arginine 10 mg

Indications/Uses : Substitution treatment of HTN &/or stable CAD (patients w/ history of MI &/or revascularisation) in adult patients adequately controlled w/ bisoprolol & perindopril given concurrently at same dose level. 5 mg/5 mg: Stable chronic heart failure w/ reduced systolic left ventricular function in adult patients adequately controlled w/ bisoprolol & perindopril given concurrently at same dose level.

New Molecule

3 New

New Formulation

1 New

Invega Trinza

New Indication

1 New

Xtandi

New Brand

15 New

pill identifier

Shape

Form

Color 1

Color 2

Markings

Shape

Form

Color 1

Color 2

Search Drug Information, Images & Medical News | MIMS Malaysia

Ozempic

Erleada

Galvus Met

Xofluza

Forxiga

Crestor

Cosyrel